Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Alder Biopharmaceuticals
Thumbnail
November 08, 2019

2020 CGRP sales hopes look far fetched

Thumbnail
October 14, 2019

Lack of drive could slow down Reyvow sales

Article image
Vantage logo
October 08, 2019

Deal-depressed third quarter leaves nowhere to hide

Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.

Article image
Vantage logo
September 16, 2019

Alder won’t solve Lundbeck’s headaches

Lundbeck needed a deal, but it could struggle against strong competition in migraine.

Article image
Vantage logo
August 30, 2019

Upcoming events – pivotal tests approach for Lilly and Biohaven

Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.

Article image
Vantage logo
May 02, 2019

Faint hope for Alder as Teva bucks dismal migraine trend

Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.

Article image
Vantage logo
April 12, 2019

Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay

Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.

Article image
Vantage logo
March 21, 2019

No, aducanumab is not an Alzheimer’s drug either

Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?

Article image
Vantage logo
February 07, 2019

Lilly hopes volume can make up for late migraine entry

In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.

Article image
Vantage logo
September 28, 2018

Upcoming events – Sage and Biohaven await pivotal data

Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…

Article image
Vantage logo
September 17, 2018

Teva tries to make something out of nothing with Ajovy approval

Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up